Abstract: The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.
Type:
Grant
Filed:
January 9, 2009
Date of Patent:
April 12, 2016
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
Type:
Grant
Filed:
May 8, 2014
Date of Patent:
February 2, 2016
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTE
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: The present invention relates to use of very small embryonic-like (VSEL) stem cells in therapies for ocular disease involving retinal degeneration or dysfunction. The invention also included pharmaceutical compositions made with VSELs which may be used to restore lost vision or reduce or halt vision loss due to diseases or disorders of the retina, or other diseases or retinal injuries that would benefit from stem cell replacement therapy.
Type:
Application
Filed:
May 31, 2013
Publication date:
January 28, 2016
Applicant:
The Schepens Eye Research Institute, Inc.
Inventors:
Kameran LASHKARI, Michael YOUNG, Sarah EMINLI-MEISSNER, Wayne MARASCO, Robert PRETI
Abstract: Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.
Type:
Application
Filed:
February 19, 2014
Publication date:
December 31, 2015
Applicants:
VA BOSTON HEALTHCARE SYSTEM, SCHEPENS EYE RESEARCH INSTITUTE, CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Markus H. Frank, Natasha Y. Frank, Bruce Ksander
Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.
Type:
Grant
Filed:
November 5, 2010
Date of Patent:
September 22, 2015
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTE
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature. The present invention is further directed to a culture medium for growing or maintaining retinal stem cells, and methods of maintaining adult retinal cells in culture. The present invention is further directed to methods of treating a treating an eye with retinal dystrophy using retinal stem cells, and an eye with glaucomatous injury with retinal stem cells. The present invention is further directed to kits for harvesting extra-retinal ocular tissue comprising a sterile container and a harvesting solution, wherein the kit allows the survival of the tissue until later dissociation of cells from the tissue.
Type:
Grant
Filed:
February 15, 2007
Date of Patent:
June 23, 2015
Assignee:
The Schepens Eye Research Institute, Inc.
Inventors:
Kameran Lashkari, Marie Shatos, Tat Fong Ng
Abstract: The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.
Type:
Grant
Filed:
January 13, 2010
Date of Patent:
March 17, 2015
Assignees:
Schepens Eye Research Institute, Lubris LLC
Inventors:
Edward R. Truitt, III, Benjamin Sullivan, David Sullivan
Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.
Type:
Grant
Filed:
September 20, 2013
Date of Patent:
February 3, 2015
Assignees:
The Regents of the University of California, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: The following disclosure provides compositions and methods for the repairing of a diseased or disordered retina, for example, in patients suffering from age-related macular degeneration (AMD).
Type:
Application
Filed:
December 23, 2013
Publication date:
August 21, 2014
Applicants:
The Charles Stark Draper Laboratory, Inc., The Schepens Eye Research Institute, Inc.
Inventors:
Sarah L. Tao, Stephen Redenti, Magali Saint-Geniez, Michael Young, Patricia D'Amore
Abstract: The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
Type:
Application
Filed:
October 17, 2013
Publication date:
May 22, 2014
Applicant:
The Schepens Eye Research Institute
Inventors:
Michael J. Young, Budd A. Tucker, Petr Y. Baranov
Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.
Type:
Application
Filed:
September 20, 2013
Publication date:
April 10, 2014
Applicants:
Schepens Eye Research Institute, The Regents of the University of California
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: This application discloses pharmaceutical compositions (e.g., oral, parenteral or topical ophthalmic formulations) for treating Fuchs endothelial corneal dystrophy (FECD) with one or more Nrf2 activators and/or mitochondrially targeted antioxidants. The compositions may be topically administered to the eye and are effective in the treatment of FECD. The invention further provides methods of treating FECD by in a subject in need of such treatment by topical application of one or more Nrf2 activators and/or mitochondrially of the invention.
Type:
Application
Filed:
June 30, 2011
Publication date:
October 31, 2013
Applicant:
The Schepens Eye Research Institute Inc.
Abstract: The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
Type:
Grant
Filed:
June 14, 2011
Date of Patent:
October 22, 2013
Assignee:
The Schepens Eye Research Institute
Inventors:
Michael J. Young, Budd A. Tucker, Petr Y. Baranov
Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.
Type:
Grant
Filed:
November 5, 2010
Date of Patent:
October 22, 2013
Assignees:
The Regents of the University of California, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.
Type:
Grant
Filed:
July 2, 2012
Date of Patent:
October 8, 2013
Assignees:
The Regents of the University of California, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan